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The AMP-activated protein kinase (AMPK) acts as a cellular energy sensor.
Once switched on by increases in cellular AMP : ATP ratios, it acts to restore
energy homeostasis by switching on catabolic pathways while switching off
cell growth and proliferation. The canonical AMP-dependent mechanism of
activation requires the upstream kinase LKB1, which was identified geneti-
cally to be a tumour suppressor. AMPK can also be switched on by
increases in intracellular Ca2þ, by glucose starvation and by DNA damage
via non-canonical, AMP-independent pathways. Genetic studies of the role
of AMPK in mouse cancer suggest that, before disease arises, AMPK acts as
a tumour suppressor that protects against cancer, with this protection being
further enhanced by AMPK activators such as the biguanide phenformin.
However, once cancer has occurred, AMPK switches to being a tumour
promoter instead, enhancing cancer cell survival by protecting against meta-
bolic, oxidative and genotoxic stresses. Studies of genetic changes in human
cancer also suggest diverging roles for genes encoding subunit isoforms,
with some being frequently amplified, while others are mutated.1. Introduction
The AMP-activated protein kinase (AMPK) is best known as a sensor of both cel-
lular [1–3] and whole body [4,5] energy status. AMPK is activated when ATP
bound at a key site on its g regulatory subunit is displaced by AMP and/or
ADP, causing conformational changes that trigger allosteric activation, as well
as promoting net phosphorylation (and consequent activation) of the catalytic
subunit by upstream kinases. As ADP rises and ATP falls during situations of cel-
lular energy stress, the reaction catalysed by adenylate kinases (2ADP$ATP þ
AMP) is displaced rightwards, ensuring that AMP rises to an even larger extent
than ADP [6], thus activating AMPK in a very sensitive manner. AMPK is also
activated by increases in intracellular Ca2þ [7–9], by glucose starvation [10]
and by DNA damage [11–13] via non-canonical, AMP/ADP-independent mech-
anisms. By phosphorylating downstream targets that switch on catabolic
pathways, while switching off anabolic pathways and other ATP-consuming pro-
cesses such as progress through the cell cycle, AMPK not only promotes ATP
synthesis but also restricts cell growth and proliferation in an attempt to restore
energy homeostasis and maintain cell viability.
Given this propensity to switch off cell growth and proliferation, and the dis-
covery that the principal upstream kinase phosphorylating and activating AMPK
was the well-established tumour suppressor LKB1 [14–16], it seemed likely that
AMPK would play a beneficial role (Dr Jekyll!) in cancer and act as a tumour
suppressor. There is indeed evidence supporting this, at least in some cancer
types, as well as for the obvious corollary that AMPK activators should delay
tumorigenesis in those cancers. However, there is contrasting evidence that, in
other contexts, the presence of AMPK may play a malevolent role (Mr Hyde!)
to promote cancer, most likely by protecting transformed cells against stresses
caused either when their growth rate outstrips the ability of their blood supply
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thereby potentially decrease survival of the patient, and in
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Figure 1. Schematic diagram of the structure of AMPK heterotrimers, with
the different subunits colour coded (a, yellow; b, lilac; g blue). Based on
a structure of the human a1b2g1 complex [19], although the structures
of a2b1g1 [17] and a1b1g1 [18] complexes are very similar.
rnal/rsob
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AMPK appears to exist universally as heterotrimeric com-
plexes comprising catalytic a subunits and regulatory b and
g subunits. Genes encoding these three subunits are found in
the genomes of essentially all eukaryotes, suggesting that the
AMPK system evolved very early during eukaryotic evolution
[2]. In mammals, there are multiple genes encoding each sub-
unit, generating two a (a1, a2), two b (b1, b2) and three g
subunits (g1, g2, g3). These paralogues appear to have arisen
during the two rounds of whole genome duplication that are
thought to have occurred during the early development of
the vertebrates [3]. The seven gene products (not counting
splice and/or start-site variants) can form up to 12 abg combi-
nations that display subtle differences in regulation and in
tissue and subcellular distribution [3].
Crystal structures of three abg combinations from humans,
i.e. a2b1g1 [17], a1b1g1 [18] and a1b2g1 [19], as well as partial
structures from mammals [20,21], budding yeast [22] and fis-
sion yeast [23,24], are now available. The generalized
structure of a heterotrimeric AMPK complex is represented in
a highly schematic form in figure 1. A current limitation of
the existing structures of heterotrimeric complexes is that, in
every case, the constructs were crystallized in active confor-
mations, with the catalytic subunit phosphorylated at the
activation site and allosteric activators bound at the regulatory
sites. Due to the lack of structures in inactive conformations, we
still only have a partial understanding of the conformational
changes involved in the activation process.
2.1. Structure of the a subunits
Each AMPK-a subunit (coloured yellow in figure 1) has an
N-terminal kinase domain with the small N-terminal lobe
and larger C-terminal lobe typical of all members of the eukary-
otic protein kinase (ePK) family, with the ATP-binding catalytic
site in the cleft between the two lobes. Like many other ePKs,
AMPK is only significantly active after phosphorylation
within the so-called ‘activation loop’ of the C-lobe. In AMPK,
the target for phosphorylation is a highly conserved threonine
residue, which is conventionally referred to as Thr172 [25]
although the exact residue numbering varies with species and
isoform (in the view of figure 1, Thr172 is located on the far
side of the C-lobe). In other ePKs, phosphorylation within the
activation loop changes its conformation to reorient residues
involved in both catalysis and protein substrate binding, thus
greatly enhancing the reaction rate [26]. The principal upstream
kinase phosphorylating Thr172 on AMPK was identified in
2003 to be a complex containing LKB1 and two accessory sub-
units, STRAD-a or -b and MO25-a or -b [14]. Binding of
STRAD-a or -b (which are pseudokinases, structurally relatedto protein kinases but not active) is required for the kinase
activity of LKB1, whereas MO25-a or -b appear to have a struc-
tural role to stabilize the complex [27]. The gene encoding LKB1
(called STK11 in humans) had been previously identified as
being involved in Peutz–Jeghers syndrome, a rare inherited
cancer susceptibility; humans with this syndrome are almost
always heterozygous for loss-of-function mutations in STK11
[28]. Their major clinical problem is the development of
frequent but benign intestinal polyps, which appear to be
caused by haploinsufficiency in STK11. However, they also
have a greatly increased risk of developing malignant cancers
at multiple locations due to loss of heterozygosity in STK11,
and often die at a relatively early age from such malignancies
[28]. Loss-of-function mutations in STK11 also frequently
occur in many sporadic (i.e. non-inherited) cancers, especially
in the commonest form of lung cancer, adenocarcinoma
[3,29,30] (see also §6). LKB1 is therefore a classical tumour sup-
pressor, and although its sequence showed that it was a
member of the ePK family, the downstream target(s) that it
phosphorylated were completely unknown until the finding
that it phosphorylated and activated AMPK [14–16].
Following the kinase domain on each AMPK-a subunit
(figure 1) is a compact bundle of three a-helices termed the
autoinhibitory domain (a-AID) [18–20,24]. When ATP rather
than AMP is bound at the regulatory site(s) on the g subunit
(see below), the a-AID is thought to interact with the kinase
domain to clamp it in an inactive conformation [24]. The
a-AID is linked to the globular C-terminal domain of the a
subunit (a-CTD) by the a-linker, shown schematically as a
yellow chain in figure 1. The a-linker is a region in an extended
conformation that contains two conserved segments termed
a-regulatory interaction motifs (a-RIM1 and a-RIM2) [31].
These interact with the surface of the g subunit containing
the key regulatory adenine nucleotide-binding site (see §2.3),
and movement of this linker is thought to transmit the effects
of AMP or ADP binding from the regulatory g subunit to the
catalytic a subunit (see §2.4).
royalsocietypublishing.org/journal/rsob
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32.2. Structure of the b subunits
The b subunits (coloured lilac in figure 1) contain two con-
served regions, the central carbohydrate-binding module
(b-CBM) and the C-terminal domain (b-CTD), these being
the only regions of the b subunits that are resolved in the cur-
rent heterotrimer structures. The b-CBM causes a proportion
of AMPK in mammalian cells to bind to glycogen particles
[32,33]. One function of this may be to co-localize AMPK
with glycogen synthase, the key enzyme of glycogen synthesis
also found at the surface of the glycogen particle, both isoforms
ofwhich are phosphorylated and inactivated byAMPK [34,35].
Theb-CBM, however, also has other functions (see §3.2 below).
The b-CTD, on the other hand, plays a key structural role as the
‘core’ of the heterotrimeric complex, in that it cross-links
the a-CTD and the g subunit, via interactions that are highly
conserved from fungi to mammals [21–23].
2.3. Structure of the g subunits
Theg subunits (colouredblue in figure 1) are of particular interest
because they contain the regulatory adenine nucleotide-binding
sites. In all species, the g subunits contain four tandem repeats
of a sequence motif of around 60 amino acids known as a CBS
repeat, so-named by Bateman [36] because they are also present
in the enzyme Cystathione b-Synthase and invariably occur as
tandem repeats. CBS repeats have been identified in around
75 proteins in the human genome [37], and are also found in
archaea and bacteria. Proteins containing them usually have
just two tandem repeats, but the AMPK-g subunits are unusual
in having four. A single pair of repeats (known as a Bateman
domain or module) forms a pseudodimer with a cleft between
the repeats that (due to the approximate twofold symmetry)
can provide two ligand-binding sites, although often only
one is used. Bateman modules usually bind regulatory ligands
containing adenosine (e.g. AMP, ATP, S-adenosyl methionine,
NAD, diadenosine polyphosphate) or, less often, guanosine
[37,38]. Consistent with this, the CBS repeats in the AMPK-g
subunits provide the critical binding sites for the regulatory
nucleotides AMP, ADP and ATP [38]. The four CBS repeats in
every AMPK-g subunit form two Batemanmodules that assem-
ble ‘head to head’ to form a flattened disc with the adenine
nucleotide-binding sites located close together in the centre,
lining a narrow aqueous channel (figure 1) [17–19,21]. Given
the presence of four repeats, it might have been expected that
AMPK-g subunits would bind four molecules of nucleotide,
but all existing crystal structures suggest that they bind only
three. These sites are now numbered according to which repeat
in the linear sequence (CBS1 through CBS4) provides residues
that bind the adenosine moiety of the nucleotide [39] (the phos-
phate groups may interact with residues from more than one
repeat). Using this nomenclature, adenine nucleotides bind at
CBS1, CBS3 and CBS4, while the CBS2 site appears to be
always unoccupied. The CBS3 site is primarily accessible to sol-
vent from one side of the disc of the g subunit (facing the
viewer in figure 1), and the CBS1 and CBS4 sites from the other.
2.4. Canonical regulation of AMPK by adenine
nucleotides
AMP-activated protein kinase received its name [40] because it
is allosterically activated by 50-AMP [41]. When the assays areperformed at physiologically relevant ATP concentrations
(5 mM) allosteric activation can be as much as 10-fold [42].
However, even before LKB1 was identified as the upstream
kinase and Thr172 as the phosphorylation site, it was realized
that increases in the AMP : ATP ratio also promoted net phos-
phorylation of AMPK in intact cells [43]. This is now known to
occur because AMP both enhances phosphorylation by LKB1
[44,45] and inhibits dephosphorylation by protein phospha-
tases [46]. Both effects are due to the binding of AMP to the
substrate, AMPK, and not to the upstream kinase or phospha-
tase; indeed the LKB1 complex appears to have a constant
activity in both energy-stressed and unstressed conditions
[47]. To summarize, AMP binding has three effects on
AMPK: (i) promoting Thr172 phosphorylation; (ii) inhibiting
Thr172 dephosphorylation; (iii) triggering allosteric activation
of kinase already phosphorylated on Thr172. These three
mechanisms act synergistically and make the system respond
to small increases in AMP in a very sensitive manner. It was
subsequently reported that the effects of AMP binding on
Thr172 phosphorylation [48] and dephosphorylation [20],
although not on allosteric activation, could be mimicked by
ADP, at least in cell-free assays. Our group has confirmed
this, but found that the effect required concentrations of ADP
up to 10-fold higher than those of AMP, at least for complexes
containing g1 and g3 (g2-containing complexes are more
sensitive to ADP) [42,45]. Overall, we believe that increases in
the AMP : ATP ratio remain the most important activating
signal in vivo, although increases in the ADP : ATP ratio
might make a secondary contribution.
How are these three effects of adenine nucleotide binding
mediated by the three binding sites on the AMPK-g subunits?
Although it might seem tempting to propose that each effect is
due to binding of nucleotides at one of the three sites, that
simple model now seems to be untenable. Instead, all three
effects appear to be due to binding of nucleotide at a single
critical site, CBS3. The evidence supporting this may be briefly
summarized as follows.
(1) CBS4 normally appears to contain a tightly bound ‘non-
exchangeable’ molecule of AMP [21]. Similarly, although
CBS1 can bind AMP in cell-free assays, it is estimated to
have a 10-fold higher affinity for ATP than AMP. Since
ATP is usually present in cells at up to 100-fold higher
concentrations than AMP, this suggests that, in intact
cells, CBS1 would always be occupied by ATP [49].
This leaves CBS3 as the site where ATP and AMP (or
ADP) could exchange with each other.
(2) The R531G mutation in the AMPK-g2 subunit, one of up
to 14 mutations that cause an inherited heart disease [50],
completely blocks both allosteric activation and increased
net Thr172 phosphorylation by AMP [38,51]. Although it
is actually located in CBS4, the positively charged side
chain of Arg531 interacts with the a-phosphate of AMP
bound in CBS3 [21,49] (note that in [21] the CBS3 site
was referred to as site 1; see [39] for revised nomenclature
of binding sites).
If CBS3 is the critical site for all three effects of AMP, what are
the functions of nucleotide binding at CBS1 and CBS4? All
three sites are located very close together in the centre of
the g subunit, where they are likely to interact with each
other. Gu et al. [49] have provided evidence that binding of
ATP at CBS1 alters the conformation of the neighbouring
royalsocietypublishing.org/journal/rsob
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4CBS4 site such that the latter binds only AMP in a non-
exchangeable manner. They further propose that binding of
AMP at CBS4 then enhances the affinity of AMP relative to
ATP at CBS3. In particular, binding of AMP at CBS4 reposi-
tions the side chain of Arg531 such that it provides an
additional positive charge to bind the two negatively charged
oxygen atoms on the a-phosphate of AMP in CBS3 (note that
the a-phosphates of ADP and ATP, unlike that of AMP, carry
only single negative charges) [49]. If this is correct, constitu-
tive binding of ATP to CBS1 and AMP to CBS4 effectively
‘tunes’ the affinity of the CBS3 site for the different nucleo-
tides that can bind there. This model explains how AMPK
achieves the difficult task of sensing changes in AMP in the
presence of much higher concentrations of ATP and ADP.
An additional explanation for the preference of the CBS3
site for AMP over ATP is that all three sites on the AMPK-g
subunits appear to preferentially bind free ATP42 rather
than the Mg.ATP22 complex [21,23,38,49], although only
around 10% of ATP in cells is thought to be present in the
Mg2þ-free form.
How is the effect of displacement of ATP by AMP at CBS3
transmitted to the catalytic (a) subunit? Consistent with the
idea that CBS3 is the critical site for activation, the heterotrimer
structures show that, whenAMP is bound at CBS3, thea-linker
binds to that face of the g subunit, with a-RIM1 binding across
the unoccupied CBS2 site and a-RIM2 physically contacting
AMP bound at CBS3 (figure 1). Although there are no crystal
structures to confirm this, other biophysical approaches
suggest that, when ATP displaces AMP at CBS3, the a-linker
dissociates from the surface of the g subunit containing the
CBS3 site [19,52]. This is thought to release the a-AID to
rotate back into its inhibitory position behind the kinase
domain, with this being prevented when AMP is bound at
CBS3 by the interaction of the a-linker with the CBS3 site.
Consistent with this model, mutations that would affect the
interactions between a-RIM1/a-RIM2 and the g subunit
abolish allosteric activation by AMP [31].
While this model nicely accounts for allosteric activation
by AMP, the accompanying conformational changes may
also alter the exposure of Thr172 for phosphorylation and
dephosphorylation, although that aspect is currently less
well understood. It also remains unclear why ADP binding
has effects on Thr172 phosphorylation despite the fact that,
unlike AMP, it does not cause allosteric activation. Finally,
as well as the ‘canonical’ activation by changes in adenine
nucleotide ratios discussed above, AMPK can also be acti-
vated by several non-canonical mechanisms that will now
be briefly described.
2.5. Non-canonical activation by increases in
intracellular Ca2þ, by glucose deprivation
and by DNA damage
As well as LKB1, Thr172 can also be phosphorylated by the
Ca2þ/calmodulin-dependent protein kinase CaMKK2 [7–9],
whichmeans that AMPK can be activated by increases in intra-
cellular Ca2þ ions even in the absence of any changes in
adenine nucleotide ratios. This occurs, for example, in response
to hormones and agonists sensed by G protein-coupled recep-
tors that are coupled via Gq/G11 to release inositol-1,4,5-
trisphosphate (IP3) from the plasma membrane, which in
turn triggers release of Ca2þ from the endoplasmic reticulum.Such agonists include, in endothelial cells, thrombin acting
at protease-activated receptors and vascular endothelial cell
growth factor acting at VEGF receptors [53,54] as well as, in
specific neurons of the hypothalamus, ghrelin acting at
GHSR1 receptors [55]. The latter effect is important in pro-
motion of appetite during fasting [5], and the role of
CaMKK2 in this pathway can explain previous findings that
CaMKK2 inhibitors depress appetite in wild-type mice,
although not in CaMKK2 knockouts [56].
It has been known for many years that glucose deprivation
of mammalian cells activates AMPK [57], and this treatment is
often used to switch on AMPK in cultured cells. In fact, genes
encoding the budding yeast orthologue of AMPK (the SNF1
complex) were originally identified via mutations that pre-
vented the normal changes in gene expression in response to
glucose deprivation [58]. For many years, it was assumed
that glucose deprivation activated AMPK by interfering with
catabolic ATP production, and thus activated AMPK via the
canonical, AMP-dependent mechanism (§2.4). This does
indeed seem to be the case in some established tumour cell
lines, perhaps because they are highly glycolytic and have a
high dependency on glucose for ATP production. However,
in other cells such as immortalized mouse embryo fibroblasts
(MEFs) it has been found that glucose deprivation activates
AMPK without changing AMP : ATP or ADP : ATP ratios, as
long as an alternative carbon source such as glutamine is avail-
able; similar AMP/ADP-independent activation is also
observed in rat liver during starvation in vivo [10]. In such
cases, activation is thought to occur via a complex mechanism
involving the direct sensing of the glycolytic intermediate
fructose-1,6-bisphosphate (FBP) by FBP aldolase, and the
recruitment of AMPK to a ‘super-complex’ on the lysosomal
membrane involving the vacuolar-ATPase, the Ragulator com-
plex, Axin, LKB1 and AMPK. Although this mechanism may
operate in tumour cells that are dependent on rapid glucose
uptake, a full discussion of it is beyond the scope of this article
and interested readers are referred to the original papers
[10,59,60] or a recent review [2].
A third type of non-canonical activation of AMPK occurs
in response to DNA damage. This was originally reported to
occur in response to the topoisomerase II inhibitor etoposide
[12], and was later observed following treatment of cells with
ionizing radiation [13]. Both treatments cause double-strand
breaks in DNA, and are often used in cancer treatment.
Double-strand DNA breaks are known to be detected by
ATM, a member of the phosphatidylinositol 3-kinase-like
kinase (PIKK) family, and the effects of etoposide to activate
AMPK were originally claimed to be dependent on ATM,
because the effects appeared to be reduced in ATM-deficient
cells [12]. In addition, ATM is known to phosphorylate LKB1
at Thr366 [61], and it was reported that AMPK activation by
etoposide in cells was reduced by siRNA-mediated knock-
down of either ATM or LKB1 [12,62], suggesting the
existence of a kinase cascade from ATM to LKB1 to AMPK.
However, this cannot be the primary mechanism, because
both etoposide [12] and ionizing radiation [13] still activate
AMPK in LKB1-null tumour cells. Moreover, our laboratory
showed that AMPK activation by etoposide was not blocked
by the ATM inhibitor KU-55993, despite the fact that the
inhibitor did block phosphorylation of known ATM sub-
strates [11]. We went on to show that AMPK activation by
etoposide in LKB1-null cells was mediated by Thr172 phos-
phorylation catalysed by CaMKK2, and that this was
AICAR ZMP AMP
C13 C2
PF-739 MK-8722
metformin
sorafenib
berberine
phenformin
arctigenin
(a)
(b)
(c)
Figure 2. Structures of a number of AMPK activators. They have been classified according to their mechanisms of activation of AMPK (see §§3.1–3.3). (a) Pro-drugs
that are converted inside cells to AMP analogues. (b) Compounds that bind in the allosteric drug and metabolite (ADaM) site. (c) Compounds that activate indirectly
by inhibiting mitochondrial ATP synthesis.
royalsocietypublishing.org/journal/rsob
Open
Biol.9:190099
5associated with increases in Ca2þ within the nucleus. Interest-
ingly, onlyAMPK complexeswithin the nucleus containing the
a1 isoform were activated, even though a2 was also expressed
in the cells under study. Perhapsmost interesting of all, activat-
ing AMPK in LKB1-null cells (using the Ca2þ ionophore
A23187 to activate CaMKK2) provided significant protection
against cell death induced by etoposide. The most likely mech-
anism to explain this was that A23187 caused a G1 cell cycle
arrest, thus restricting entry of cells into S phase where they
are particularly susceptible to DNA damage. This hypothesis
was supported by the fact that the G1 cyclin-dependent
kinase inhibitor palbociclib caused avery similar degree of pro-
tection against cell death in those cells where it caused G1
arrest, but not in those where it did not [11]. These results are
significant, because they suggest that genotoxic treatments
such as etoposide and ionizing radiation might be more effec-
tive for cancer treatment if they were combined with inhibitors
that prevent AMPK activation, and the consequent protectionthat AMPK can provide against genotoxic stress. This point is
addressed further in §6 below.3. Pharmacological activation and
inhibition of AMPK
The realization that AMPK acts as a metabolic master switch,
which transforms cellular metabolism from an anabolic to a
catabolic state, originally suggested that activators of AMPK
might be useful in treating disorders of energy balance such
as obesity and type 2 diabetes [63]. Similarly, the discoveries
that AMPK inhibited both cell growth and cell proliferation
suggested that activators might also be useful in the treatment
of cancer [64]. Over the past 20 years, scores of compounds that
pharmacologically activate AMPK have been described, a few
of which are shown in figure 2. These are discussed in §§3.1–
3.3 according to their likely modes of action. There has been
royalsocietypublishing.org/journal/rsob
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6much less emphasis on the development of inhibitors, but
these are briefly discussed in §3.4.
3.1. Pro-drugs that are converted inside cells to AMP
analogues
The first compound shown to activateAMPK in intact cellswas
the adenosine analogue 5-aminoimidazole-4-carboxamide
riboside (AICAR), which is taken up into cells via adenosine
transporters [65] and converted by adenosine kinase into the
equivalent monophosphorylated nucleotide, ZMP [66–68]
(figure 2a). ZMP mimics all three of the effects of AMP
described in §2.4 [66], and AICAR has been much used as an
experimental tool to activate AMPK in intact cells and in vivo.
It should be noted, however, that ZMP is much less potent as
an AMPK activator than AMP, and AICAR only activates
AMPK in intact cells because intracellular ZMP accumulates
tomillimolar concentrations, even higher than the external con-
centrations of AICAR [66]. The use of AICAR is no longer
recommended by the present authors, because ZMP has
known off-target effects (e.g. it also mimics the effects of
AMP to activate skeletal muscle glycogen phosphorylase [69]
and inhibit hepatic fructose-1,6-bisphosphatase [67,70]), and
because much more specific activators are now available.
One such is C13, a derivative of another adenosine analogue
termed C2 that has been esterified on two oxygen atoms of
its phosphonate group to make it more cell permeable [71].
C13 is indeed readily taken up by cells, but is then converted
into C2 by cellular esterases (figure 2a). Remarkably, C2 is an
evenmore potent activator of AMPK thanAMP itself, although
it should be noted that it is specific for AMPK complexes con-
taining the a1 isoform, and is inactive on a2 complexes [72].
The high affinity of C2 may arise because it binds, unexpect-
edly, to the AMPK-g subunits in a somewhat different
orientation than AMP [73].
3.2. Compounds that bind in the allosteric drug and
metabolite (ADaM) site
In the structures of AMPK heterotrimers containing either b1
[17,18] or b2 [19], the b-CBM interacts with the N-lobe of the
kinasedomainof thea subunit via the surface opposite to its gly-
cogen-binding site (figure 1). The cleft between these domains
forms the binding site for novel ligands acting on AMPK,
which in most cases came out of high-throughput screens that
searched libraries of synthetic chemicals for allosteric activators
of AMPK. The first to be discovered was the thienopyridone
A-769662 [74] but at least 10 have now been reported, including
PF-739 [75] and MK-8722 [76] (figure 2b). All activate b1 com-
plexes with higher potency than b2 complexes, and this makes
some of them (including A-769662 [77]) highly selective for the
former. As well as causing allosteric activation, binding of
these compounds also inhibits Thr172 dephosphorylation in
cell-free assays [78,79], although in intact cells the predominant
effect appears to be allosteric, since large changes inphosphoryl-
ation of the AMPK target acetyl-CoA carboxylase in response to
these agonists are usually only accompanied bymodest changes
in Thr172 phosphorylation [78].
One of the curious features of the ligands currently known
to bind at this site is that almost all of them are synthetic chemi-
cals rather than natural products. However, many in the field
believe that these compounds may be mimicking the effect ofsome natural metabolite that binds to this site, which is why
it has been termed the ‘allosteric drug and metabolite’
(ADaM) site [80]. The only natural product currently known
to bind to this site is salicylate, a compound made by plants
that acts as a hormone signalling infection by pathogens [81].
In the form of extracts of willow bark, salicylates have been
used by humans as medicines since ancient times, and they
are still in very wide use as the synthetic derivative acetyl sal-
icylic acid (ASA or aspirin), which is rapidly broken down to
salicylate once it enters the circulation. Although aspirin itself
is a potent irreversible inhibitor of the cyclo-oxygenases
involved in biosynthesis of prostanoids such as thromboxanes
[82], salicylate activates AMPK by direct binding at the ADaM
site, which occurs at concentrations reached in plasma of
patients taking high doses of aspirin and other salicylate-
based drugs [81]. Interestingly, regular use of aspirin, usually
taken to reduce the formation of blood clots via inhibition of
thromboxane synthesis, is associated with a reduced incidence
of cancer [83]. Whether this can be explained entirely by inhi-
bition of cyclo-oxygenases, or whether it involves some other
target such as AMPK, currently remains unclear.
3.3. Compounds, including biguanides, that activate
AMPK indirectly by inhibiting mitochondrial ATP
synthesis
Metformin and phenformin (figure 2c) are synthetic bigua-
nides derived from galegine (isoprenyl guanidine) [84], a
natural product from the plant goat’s rue or Galega officinalis,
which was well known as a herbal remedy in seventeenth
century England [85]. Both biguanides were introduced for
treatment of type 2 diabetes in the 1950s, although phenfor-
min was withdrawn in most countries in the 1970s because
its use was associated with the rare but life-threatening side
effect of lactic acidosis. The risk of lactic acidosis is much
lower with metformin, which has subsequently become the
drug of first choice in the treatment of type 2 diabetes world-
wide. Although biguanides have been used since the 1950s,
the first clues to their mechanism of action did not emerge
until 2000, when they were reported to inhibit complex I
of the mitochondrial respiratory chain, thus explaining the
risk of lactic acid accumulation [86,87]; they have sub-
sequently also been shown to inhibit the mitochondrial ATP
synthase [88]. Clearly, inhibition of mitochondrial ATP syn-
thesis would be expected to increase cellular ADP : ATP and
AMP : ATP ratios and thus activate AMPK by the canonical
mechanism. Indeed, activation of AMPK by biguanides in
intact cells and in vivo was reported in 2001 [89], and it was
subsequently confirmed that this was caused by increases in
AMP and/or ADP [51], although metformin may also activate
AMPK via the non-canonical lysosomal pathway [90]. Metfor-
min has two major clinical effects: (i) inhibiting glucose
production by the liver and (ii) enhancing insulin sensitivity
of tissues such as liver and skeletal muscle. Surprisingly,
studies with liver-specific double AMPK (a12/2 a22/2)
knockout mice showed that the rapid effects of metformin on
liver glucose production were AMPK independent, despite
the fact that they were accompanied by increases in cellular
AMP : ATP ratios [91]. These acute effects of metformin now
appear to be due to direct allosteric inhibition of the gluconeo-
genic enzyme fructose-1,6-bisphosphatase by AMP [70].
Despite this, studies of mice with double knock-in mutations
royalsocietypublishing.org/journal/rsob
Open
Biol.9:190099
7of the single serine residues that are targeted by AMPK in
ACC1 (S79A) and ACC2 (S212A) suggested that the longer
term insulin-sensitizing effects of metformin are indeed
mediated by AMPK [92]. These mice, in which AMPK no
longer acutely inhibits fatty acid synthesis or activates fatty
acid oxidation, accumulate excess di- and tri-glycerides in
liver and muscle, which is accompanied by insulin resistance.
Althoughwild-typemice developed a similar degree of insulin
resistance when placed on a high-fat diet, insulin sensitivity in
the knock-in mice did not deteriorate further, possibly because
they were already synthesizing so much fat. However, when
the high-fat-fed mice were treated with metformin for six
weeks, this reversed the insulin resistance of the wild-type
mice but had no effect in the knock-in mice. Thus, the longer
term effects of metformin on insulin sensitivity, although not
its short-term effects on hepatic glucose production, are due
to modulation of lipid metabolism by AMPK, most likely by
reducing the excessive storage of lipids in tissues such as
liver and skeletal muscle [92].
Following the initial findings that AMPK was activated by
biguanides [89], and that the tumour suppressor LKB1 acted
upstream of AMPK [14], the question of whether biguanide
use had any influence on cancer was addressed. Retrospective
studies suggested that the use of metformin in patients with
type 2 diabetes in the Tayside region of Scotlandwas associated
with a significant (around 30%) reduction in the incidence of
cancer [93]. This association has since been confirmed in
studies of many other diabetic cohorts [94–96], although its
validity has been challenged due to the possibility of time-
related biases [97] and it remains just a correlation, with no
proof of direct causation. In addition, even if the association
is valid, it does not necessarily imply that metformin acts
directly on AMPK within the tumours themselves, rather
than indirectly via AMPK-dependent or -independent effects
on other tissues or organs. For example, sincemetformin is cur-
rently only used to treat type 2 diabetes, we do not know
whether its use would be associated with reduced cancer inci-
dence in subjects without diabetes (although there have been
small trials in patients with breast or endometrial cancer,
these were only ‘window-of-opportunity’ trials to assess var-
ious markers in the short period prior to surgery [98–101]).
Note also that the different cancer incidence in patients with
type 2 diabetes takingmetformin is observedwhen comparing
with those on other medications [93–96]. Metformin enhances
insulin sensitivity and thus reduces insulin release, butmanyof
the other commonly used medications, such as sulfonylureas
and glucagon-like peptide-1 agonists, work in part by enhan-
cing insulin secretion, while some subjects are even treated
directly with insulin. Insulin is, of course, a growth factor
that promotes proliferation of cells by activating the Akt path-
way. One explanation of the apparent protective effect of
metformin against cancer in patients with diabetes is therefore
that, unlike most other treatments, it reduces rather than
increases the levels of insulin, with high insulin levels being
responsible for increased cancer incidence in patients on other
medications [102]. Indeed, a related phenomenon is seen
in patients with cancer who are treated with phosphatidyl-
inositol 3-kinase (PI3 K) inhibitors, who often secrete extra
insulin to compensate for the insulin resistance induced by
the drugs, thus reducing their anti-cancer efficacy. Experiments
with mouse models suggest that this effect can be overcome by
additional dietary or pharmacological treatments that reverse
the insulin resistance induced by these drugs [103].There are many other compounds that activate AMPK by
inhibiting mitochondrial ATP synthesis, one example being
resveratrol [51], which inhibits the mitochondrial ATP
synthase [104]. Another is sorafenib, originally developed
as an inhibitor of receptor-linked tyrosine kinases such as
the VEGF and platelet-derived growth factor (PDGF) recep-
tors and used to treat some liver, kidney and thyroid
cancers [105]. However, it also activates AMPK at therapeuti-
cally relevant concentrations by inhibiting the respiratory
chain [106]. Remarkably, more than 100 natural products
derived from traditional Asian medicines have within the
last few years also been shown to activate AMPK in intact
cells [107], and the effects of at least two of them, i.e. berber-
ine [51] and arctigenin [108], appear to be due to inhibition of
complex I of the mitochondrial respiratory chain. We suspect
that many of the others may also work through inhibition of
either complex I or the ATP synthase, which are both large,
membrane-bound complexes containing no less than 44 and
14 protein subunits, respectively. It is perhaps not surprising
that many hydrophobic compounds might find inhibitory
binding sites within these complexes. This class of AMPK
activator is particularly diverse in structure (e.g. those in
figure 2c), indicating that they may interact with distinct
sites. Many of the natural products that activate AMPK
may be produced by plants to provide a chemical defence
to deter grazing by insects or other animals, or infection by
pathogens, and poisoning of complex I or the ATP synthase
would seem to represent good ways to achieve those aims.
Interestingly, many of these toxic plant products are stored
within the plants that synthesize them either in the vacuole
or in the cell wall [109], where they would not come into
contact with the plant’s own mitochondria.
3.4. AMPK inhibitors
At present, no specific AMPK inhibitors are available. The only
AMPK inhibitor that has been widely used in the literature is
compoundC (also known as dorsomorphin). Althoughdeveloped
as an AMPK inhibitor, the claim that it was specific for AMPK
came from the original report that it did not inhibit a panel of
just five other protein kinases [89]. However, in a screen
of 70 protein kinases, nine were inhibited to a greater extent
than AMPK [110], while in a more recent screen of 120 kinases
documented in the MRC Kinase Inhibitor Database (www.
kinase-screen.mrc.ac.uk/kinase-inhibitors) no less than 30
were inhibited to a greater extent than AMPK. The use of
compound C cannot therefore be recommended, even as an
experimental tool. Other AMPK inhibitors have been reported
[111,112], but have not yet been widely used.4. Downstream targets of AMPK
Once activated, AMPKphosphorylates numerous downstream
proteins, with at least 60 being identified as well-established
targets in a recent review [113]. The core recognition motif
for AMPK is well defined: it requires a basic residue (R, K or
H) either three or four residues N-terminal to the phosphory-
lated serine/threonine (referred to as the P-3 and P-4
positions) as well as hydrophobic residues (L, M, I, F or V) at
P-5 and Pþ4 [113–115]. The ACC1 isoform of acetyl-CoA car-
boxylase, which is a particularly good substrate for AMPK,
has additional specificity determinants N-terminal to this
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These are another basic residue at P-6, and an amphipathic
a-helix running from P-5 to P-16 that binds in a hydrophobic
groove on the surface of the C-lobe of the AMPK kinase
domain [116].We discuss some of these targets below, focusing
on those that may be particularly relevant to the role of AMPK
in cancer.
4.1. Proteins and genes involved in catabolic pathways
Catabolic processes switched on by AMPK are summarized
in figure 3. In many cell types, depending on the expression
of specific glucose transporters (GLUTs), AMPK activation
enhances glucose uptake. In skeletal muscle, AMPK acutely
promotes translocation of vesicles containing GLUT4 from
intracellular vesicles to the plasma membrane, in part by a
mechanism involving phosphorylation of the Rab-GAP
protein TBC1D1 [117]. In the longer term, AMPK also
increases expression of GLUT4 protein via a mechanism
that may involve direct phosphorylation of class IIa histone
deacetylases (e.g. HDAC5) [118], which appears to cause
their exclusion from the nucleus [119] and therefore promotes
net acetylation and transcriptional activation at the GLUT4
promoter. AMPK activation also acutely activates glucose
transport by the more widely expressed glucose transporter
GLUT1 [120], in part via phosphorylation and consequent
degradation of TXNIP, an a-arrestin family member that
appears to promote internalization of GLUT1 as well as
reduced levels of its mRNA [121]. In some but not all cells,
AMPK acutely stimulates glycolytic flux via a mechanism
involving direct phosphorylation of 6-phosphofructo-2-
kinase/fructose-2,6- bisphosphatase, the enzyme that makes
and breaks down fructose-2,6-bisphosphate via distinctdomains of a bienzyme polypeptide [122]. Phosphorylation
by AMPK increases the kinase activity, thus increasing the
cellular concentration of fructose-2,6-bisphosphate, a potent
allosteric activator of the glycolytic enzyme 6-phospho-
fructo-1-kinase [122]. However, this mechanism is limited
to specific cell types, because only the PFKFB2 [123] and
PFKFB3 [124] isoforms are targets for AMPK. PFKFB2 is
expressed in cardiac myocytes and some other tissues,
while alternative splicing or differential promoter usage
yields two main isoforms of PFKFB3 that differ by a short
C-terminal sequence; these are the so-called ubiquitous (or
constitutive) isoform and the inducible isoform [122]. The
expression of the inducible form is very low in most adult tis-
sues, but is increased by pro-inflammatory stimuli in
monocytes and macrophages [124] and it is constitutively
expressed in many tumour cells [125].
Although AMPK can therefore acutely activate ATP pro-
duction by glycolysis in some cell types, in the longer term
it tends to promote mitochondrial oxidative metabolism
instead, which is much more efficient in terms of ATP pro-
duction per glucose consumed (36 ATP per glucose by
oxidative metabolism, as opposed to only two by glycolysis).
Oxidative metabolism is, however, less compatible with pro-
viding precursors for cell growth, so it tends to be used to a
greater extent in quiescent rather than proliferating cells [126].
In the short term, AMPK activates the uptake of fatty acids
into mitochondria via phosphorylation of the acetyl-CoA car-
boxylase isoform ACC2 [127]. While ACC1, the first AMPK
target to be identified, is thought to produce the cytoplasmic
malonyl-CoA used in fatty acid synthesis, ACC2 localizes to
mitochondria [128] and is thought to produce the mitochon-
drial malonyl-CoA that inhibits uptake of fatty acids into
mitochondria via the carnitine:palmitoyl transferase system.
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relieves inhibition of carnitine:palmitoyl-CoA transferase-1
(CPT1), thus causing acute promotion of mitochondrial
fatty acid oxidation [127].
In the longer term, AMPK activation has several effects on
mitochondria that enhance their capacity to produce ATP at a
rapid rate. Firstly, AMPK activation promotes mitochondrial
biogenesis itself, involving increased replication of mitochon-
drial DNA as well as expression of many nuclear-encoded
mitochondrial proteins, by activating the transcriptional co-
activator PGC-1a [129]. This is effected either by direct
phosphorylation of PGC-1a [130] or by increasing the cellular
concentration of NADþ, a cofactor required for deacetylation
and activation of PGC-1a by SIRT1 [131]. Secondly, being the
major site of cellular production of reactive oxygen species,
mitochondrial components are particularly prone to oxida-
tive damage, and if this affects their function mitochondria
need to be removed and their contents recycled by the tar-
geted form of autophagy known as mitophagy. Relevant to
this, AMPK has been shown to promote both autophagy
and mitophagy either by phosphorylation of the protein
kinase that triggers autophagy, ULK1 [132,133], or by phos-
phorylation of the Ca2þ/calmodulin-dependent kinase
DAPK, generating a Ca2þ/calmodulin-independent form
that phosphorylates the key autophagy protein Beclin-1
[134]. Thirdly, mitochondria are now known to exist,
especially in quiescent cells, not as small separate organelles,
but as branching networks of tubules that can be almost as
long as the cell containing them [135]. If any regions of
such a network become damaged, they need to be segregated
off from healthy regions via the process of mitochondrial
fission, so that they become small enough to be recycled by
mitophagy. Intriguingly, AMPK activation has been shown
to promote mitochondrial fission by direct phosphorylation
of mitochondrial fission factor (MFF) [136]. These findings are
consistent with one aspect of the phenotype of skeletal
muscle-specific double AMPK knockouts (either a1 and a2[137] or b1 and b2 [138]), in which muscle accumulates
abnormally shaped and apparently malfunctioning mito-
chondria. Overall, AMPK appears to play several crucial
roles in mitochondrial homeostasis. Since mitochondria are
the main source of cellular ATP in most cells, this makes per-
fect sense for a signalling pathway that is activated by energy
stress and/or glucose deprivation.
4.2. Proteins and genes involved in anabolic pathways
As well as switching on catabolic pathways that generate ATP,
AMPK also switches off almost all major anabolic pathways
(figure 4). AMPKwas originally defined via its ability to phos-
phorylate and inactivate both acetyl-CoA carboxylase (ACC1)
and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR), the
key regulatory enzymes of fatty acid and sterol synthesis,
respectively [139,140]. Fatty acid synthesis is a significant
energy-consuming pathway in rapidly dividing tumour cells,
being a major consumer of both ATP (consumed in the ACC1
reaction) and NADPH (consumed in the two reductive steps
catalysed by the fatty acid synthase complex). Indeed, ACC1
remains one of most rapidly phosphorylated substrates for
AMPK, and the phosphorylation of Ser80 (human numbering)
on ACC1, monitored using a phosphospecific antibody,
remains the most reliable and widely used cellular marker of
AMPK function.
As well as acutely inhibiting fatty acid synthesis by direct
phosphorylation of ACC1 (which catalyses the first two steps
of fatty acid synthesis from acetyl-CoA), AMPK activation
also downregulates expression of the genes encoding ACC1
(ACACA) as well as the gene (FASN) encoding the fatty acid
synthase complex, a dimeric multienzyme polypeptide that
catalyses the remaining seven reactions leading to a saturated
C16 fatty acid (palmitate). The AMPK targets responsible for
these effects may be the transcription factors sterol response
element binding protein-1c (SREBP1c) [141] and/or the carbo-
hydrate response element binding protein (ChREBP) [142],
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by AMPK.
As well as inhibiting de novo synthesis of fatty acids, AMPK
inhibits synthesis of triglyceride and phospholipid synthe-
sis by inactivating the first enzyme (glycerol phosphate acyl
transferase, GPAT) involved in the synthesis of the common
intermediate diacylglycerol [143], although whether this is
due to direct phosphorylation of the enzyme remains unclear.
Two direct targets for AMPK are the muscle (GYS1) [34] and
liver (GYS2) [35] isoforms of glycogen synthase, which catalyse
the transfer of glucose from UDP-glucose to the growing non-
reducing ends of the glycogen particle. Both are inactivated by
phosphorylation at equivalent N-terminal sites by AMPK,
although this inactivation is over-ridden by high
concentrations of the feed-forward allosteric activator of
glycogen synthase, glucose-6-phosphate [144]. The need
to co-localize AMPK with glycogen synthase may be one
reason why AMPK-b subunit isoforms in all species carry a
carbohydrate-binding module (b-CBM; see figure 1).
Another key pathway in growing cells is biosynthesis
of nucleotides. The ribose or deoxyribose components of
nucleotides are derived from ribose-5-phosphate generated
in the pentose phosphate pathway. It has recently been
reported that PRPS1 and PRPS2, the two major isoforms of
phosphoribosyl pyrophosphate synthetase that metabolize
ribose-5-phosphate in the first step of nucleotide biosynthesis,
are phosphorylated and inactivated by direct phosphoryla-
tion by AMPK [145]. The pentose phosphate pathway also
generates NADPH that is used for fatty acid biosynthesis, as
well as for regenerating reduced glutathione used to combat
oxidative stress. The large requirement for NADPH and
nucleotide biosynthesis in rapidly proliferating cells may be
one reason why they exhibit rapid glucose uptake to provide
input of glucose into the pentose phosphate pathway.
Nucleotides are, of course, the building blocks for RNA
and DNA. In rapidly proliferating thymocytes, the addition
of actinomycin D (a general inhibitor of RNA synthesis)
reduces oxygen uptake by as much as 15% [146], suggesting
that RNA synthesis accounts for at least that percentage of
total ATP turnover. Since up to 80% of the total RNA in a
typical cell is ribosomal RNA (rRNA), synthesis of the
latter is a major anabolic pathway and consumer of energy
in proliferating cells. Consistent with this, AMPK activation
has been found to inhibit rRNA synthesis by direct phos-
phorylation of the transcription factor for RNA polymerase
I, TIF-1A (encoded by the RRN3 gene) [147].
Arguably the most important biosynthetic pathway in
proliferating cells is translation (protein synthesis). Over
50% of the dry weight of most cells is protein while, in the
proliferating thymocyte system mentioned above, inhibition
of protein synthesis reduced oxygen uptake by more than
20% [146]. AMPK switches off translation by at least two
mechanisms. Firstly, it inactivates the target of rapamycin
complex-1 (TORC1), which is known to promote the
initiation step of ribosomal protein synthesis by triggering
the phosphorylation of multiple proteins, including eukary-
otic initiation factor-4E binding protein-1 (EIF4EBP1) and
ribosomal protein S6 kinase-1 (RPS6KB1) [148]. Phosphoryl-
ation of EIF4EBP1 leads to selective translation of mRNAs
containing 50-terminal oligopyrimidine (50-TOP) sequences,
which often encode mRNAs encoding proteins required for
rapid cell growth, including most ribosomal proteins as
well as other proteins involved in translation [149]. AMPKinactivates mTORC1 by at least two mechanisms, i.e. inhibi-
tory phosphorylation of the Raptor subunit that targets the
complex to downstream targets and to the lysosome where
it is activated, and activatory phosphorylation of TSC2,
which forms a key part of the TSC1:TSC2:TBC1D7 complex.
The latter has a Rheb:GTPase activator protein (Rheb:GAP)
domain on TSC2 that converts the mTORC1-activating G
protein Rheb to its inactive GDP-bound form [150]. Secondly,
AMPK inhibits the elongation step of ribosomal protein syn-
thesis by promoting phosphorylation of elongation factor-2 at
Thr56. This residue is phosphorylated not by AMPK itself but
by elongation factor-2 kinase (EF2 K), a member of the atypi-
cal protein kinase (aPK) family that is activated by Ca2þ/
calmodulin. AMPK appears to activate EF2 K in part by
direct phosphorylation [151] and in part by inactivating
mTORC1, with EF2 K being phosphorylated and inactivated
by p70S6K1 downstream of mTORC1 [152,153].
4.3. Progress through the cell cycle
As well as inhibiting most major biosynthetic pathways,
AMPK activation can also cause cell cycle arrest (figure 4).
As long ago as 2001, it was reported that the AMPK activator
5-aminoimidazole-4-carboxamide riboside (AICAR) caused
arrest in the G1 phase of the cell cycle in HepG2 cells, which
was attributed to phosphorylation of the transcription factor
p53 at Ser15, and consequent increased expression of the G1
cyclin-dependent kinase inhibitor p21CIP1 (CDKN1A) [154].
This was followed by a demonstration that both AICAR and
low glucose caused cell cycle arrest inMEFs [155]. These effects
were at least partially dependent upon p53, because they were
reduced in p532/2 MEFs. Although both AICAR and glucose
deprivation can have off-target, AMPK-independent effects,
the effects of low glucose also appeared to be AMPK depen-
dent because they were reduced by expression of a dominant
negative AMPK mutant (a kinase-inactive AMPK-a mutant
that inhibits endogenous AMPK-a subunits by competing for
available b and g subunits). This group also reported that an
activated kinase domain construct of AMPK could directly
phosphorylate p53 at Ser15 [155]. However, the sequence
around Ser15 is not a good fit to the AMPK recognition
motif, lacking a basic residue at P-4 or P-3 (in fact, with an
acidic residue at P-4 instead). It seems more likely that the
phosphorylation of p53 observed in response to AMPK
activation is indirect.
Another potential mechanism by which AMPK causes G1
arrest involves phosphorylation of another cyclin-dependent
kinase inhibitor, p27WAF1 (CDKN1B). In breast cancer cells
(MCF-7), p27was found to be phosphorylated at its C-terminal
residue (Thr198), and this appeared to stabilize the protein,
thus increasing its expression and causing cell cycle arrest as
well as appearing to promote autophagy. Phosphorylation of
Thr198 increased in response to AICAR treatment or glucose
starvation of cells. Although some evidence was presented
that Thr198 is directly phosphorylated by AMPK, the site is
not a perfect fit to the AMPK recognition motif (for example,
being the C-terminal residue, there is no hydrophobic residue
at Pþ4), and mutation of Thr198 only had a modest effect on
phosphorylation by AMPK in cell-free assays [156]. Further
studies are therefore required to confirm that this is a direct
effect of AMPK.
Although AMPK activation by both AICAR [14] and low
glucose [60] requires the presence of LKB1, AMPK could still
royalsocietypublishing.org/journal/rsob
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11cause G1 arrest in three different LKB1-deficient tumour cell
lines if it was activated by the addition of a Ca2þ ionophore to
activate the alternative upstream kinase, CaMKK2. This effect
was abolished either by expression of a dominant negative
AMPK-a2 mutant or by a double knockout of AMPK-a1
and -a2 [157]. Thus, AMPK can cause G1 arrest even in the
absence of its tumour suppressor upstream kinase, LKB1.
Interestingly, treatment of cells with the Ca2þ ionophore
A23187 caused G1 arrest without affecting the expression of
CDKN1A or CDKN1B, despite the fact that the overall
expression of both was reduced by expression of the domi-
nant negative mutant or the double knockout [157]. Thus,
in this case changes in CDKN1A or CDKN1B expression
cannot be the sole explanation for cell cycle arrest.pen
Biol.9:1900995. AMPK and cancer—evidence from
mouse models
We will now discuss the evidence that, depending upon the
context, AMPK can act either as a tumour suppressor or as
a tumour promoter in mouse models.
5.1. AMPK—a tumour suppressor?
With the discovery that AMPK activation requires the tumour
suppressor LKB1, the realization that AMPK inhibits cell
growth and proliferation, and the epidemiological evidence
that the AMPK activator, metformin, provides protection
against cancer, it seemed increasingly likely that AMPK
would also be a tumour suppressor. One caveat was that,
soon after the discovery that LKB1 acted upstream of AMPK,
LKB1 was found to be required for the phosphorylation and
activation of at least 12 other kinases closely related to
AMPK (now referred to as the AMPK-related kinase or ARK
family), which share very similar sequences within their acti-
vation loops [158,159]. Although none of the ARKs (unlike
AMPK) are known to inhibit cell growth and proliferation,
knockdown of LKB1 using RNAi was reported to enhance
expression of SNAIL, a protein that promotes the epithelial-
to-mesenchymal transition, and hence metastasis of tumour
cells, by reducing the phosphorylation of DIXDC1 by two of
the ARKs, MARK1 and MARK4 [160]. It therefore remains
possible that at least some of the tumour suppressor effects
of LKB1 might be mediated by one or more of the ARKs,
rather than AMPK.
Confirmation of a tumour suppressor role for AMPK in vivo
required the study of tumorigenesis in AMPK knockout mice.
However, there are two isoforms of the catalytic subunit
(a1 and a2) and a global double knockout is embryonic
lethal [161], thus necessitating the use of tissue-specific
double knockouts. While this approach is now possible, it is
also very time-consuming. However, a shortcut arose with
the realization that cells of the haematopoietic lineage, includ-
ing lymphocytes, exclusively express AMPK-a1 [162]. Thus, to
study the role of AMPK in lymphomas and/or leukaemias, it
was only necessary to knock out a single gene, i.e. the Prkaa1
gene encoding AMPK-a1.
The first study to suggest thatAMPKwasa tumour suppres-
sor used a Em-Myc model [163], in which B-cell lymphoma is
induced by transgenic over-expression of the Myc oncogene
from a B-cell-specific promoter. Consistent with the idea that
AMPK-a1 is a tumour suppressor, loss of both alleles ofPrkaa1 in this model markedly accelerated development of
B-cell lymphomas, whereas loss of a single allele had an inter-
mediate effect. Em-Myc lymphoma cells and other tumour
cells expressing shRNAs targeted at AMPK-a1 were also
studied in vitro. In general, the AMPK knockdown cells exhib-
ited mTORC1 hyper-activation and increased glucose uptake
and lactate production compared with controls, and this
appeared to be due to increased expression of hypoxia-inducible
transcription factor-1a (HIF-1a) [163]. The 50-UTR of mRNA
encoding HIF-1a contains 50-TOP sequences [164] and their
translation is thus enhanced by mTORC1 activation ([165]; see
§4.2). Thus, loss of AMPK in the tumour progenitor cells
enhances glucose uptake and glycolysis even under normoxic
conditions. This is an example of the well-known ‘Warburg
effect’, inwhich tumour cells display high levels of glucose con-
sumption in order to generate precursors for biosynthesis
derived from the pentose phosphate pathway and glycolysis.
For example, ribose-5-phosphate for nucleotide biosynthesis
and NADPH for lipid synthesis are generated via the pentose
phosphate pathway, while serine (required for one-carbon
metabolismused inpurinenucleotide biosynthesis) is generated
by a pathway that branches off from the glycolytic intermediate
3-phosphoglycerate [126].
A drawback with this B-cell lymphoma model was that
Prkaa1 was knocked out globally [163], so it was not possible
to conclude that the effect was due to a cell-autonomous loss
of AMPK-a1 in the B-cell progenitors themselves, rather than
an indirect effect of loss of AMPK-a1 in some other cell type.
In an attempt to address this, wild-type mice were irradiated
to inactivate their endogenous immune system, and were
then reconstituted with haematopoietic stem cells from either
Em-Myc/Prkaa12/2 or Em-Myc/Prkaa1þ/þ mice. Interestingly,
all of the mice receiving AMPK knockout cells developed lym-
phomas, but only 20% of those receiving the AMPK wild-type
cells [163], thus supporting the idea that the effect of AMPK
loss was at least partly cell autonomous.
Another study involved crossing mice with global knock-
outs of the genes encoding p53 (Trp53) and AMPK-b1
(Prkab1), the latter being the principal b subunit isoform
expressed in T-cell precursors in the thymus [166]. Knockout
of Prkab1 caused earlier onset of T-cell lymphomas in both
homozygous and heterozygous p53 knockouts, suggesting
that b1 had a tumour suppressor role in T-cell lymphoma.
However, once again the knockout of Prkab1 in this model
was global rather than T-cell specific, so it was not possible
to conclude whether this was a cell-intrinsic effect on AMPK
in the tumour progenitor cells themselves.
A specific loss of AMPK in the tumour progenitor cells has
recently been achieved using a model of T-cell acute lympho-
blastic leukaemia/lymphoma (T-ALL) [167]. As reported
previously [168], mice with a T-cell-specific knockout of
PTEN (using Cre recombinase expressed from the Lck promo-
ter) started to develop lymphomas at about 50 days of age,
and essentially all of the mice had developed T-ALL by 150
days. While knocking out the Prkaa1 gene using the same
Lck-Cre system had no effect on its own, when combined
with PTEN knockout the lymphomas arose earlier and overall
tumour-free survival was greatly reduced (figure 5) [167].
These results suggested that basal AMPK activity in develop-
ing T cells is sufficient to provide protection against T-ALL.
However, this model also provided an excellent opportunity
to test whether treatment with biguanides would protect
against this type of cancer (see §3.3). Since the expression of
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Figure 5. Effect of T-cell knockout of AMPK (AMPK KO) and oral phenformin
on tumour-free survival in mice bearing T-cell knockout of PTEN (PTEN KO).
Where indicated, phenformin was administered in drinking water starting
from 30 days of age. Original data from [167].
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12AMPK-a1 would be absent in lymphoma cells and their
progenitors but normal everywhere else, it would also be
possible to determine whether any effect of biguanides was a
cell-intrinsic effect to activate AMPK in the tumour progenitor
cells themselves. Rather disappointingly, metformin had no
effect, which correlated with a lack of AMPK activation and a
failure to detect metformin by liquid chromatography–mass
spectrometry (LC:MS) in the thymus of micewith lymphomas.
By contrast, phenformin significantly enhanced tumour-free
survival, and this correlated with AMPK activation, and detec-
tion of phenformin by LC:MS, in the thymus of mice with
lymphoma. Intriguingly, protection against T-ALL by phenfor-
min was only observed when the tumours expressed AMPK,
with no effect in the AMPK knockouts (figure 5). Thus, protec-
tion against T-ALL by phenformin was dependent upon the
expression of AMPK in the tumour progenitor cells, and was
cell autonomous,while the failure ofmetformin to provide pro-
tection was due to lack of uptake of the drug by thymocytes.
Phenformin has also been shown recently to slow growth of
murine breast cancer cells in vivo in a mouse allograft model,
although the role of AMPK was not examined [169].
Another mouse model suggesting a tumour suppressor
role for AMPK used prostate epithelial-specific knockouts of
the Pten and Prkab1 genes [170]. Although the knockout
of Prkab1 as well as Pten did not affect prostate size, it did
result in a higher proliferative index and pathological grade.
A drawback with this model was that the prostate gland also
expresses AMPK-b2, which might have partially compensated
for lack of b1 and might be why the effects on tumorigenesis
were relatively modest.
Other evidence supporting the idea that AMPK is a tumour
suppressor comes from studies of ubiquitin ligases involved in
cellular degradation of AMPK subunits. MAGE-A3/-A6 are
closely related members of the melanoma antigen family of pro-
teins, which are normally only expressed in testis but become
re-expressed in many tumours, hence their designation as
tumour antigens [171]. MAGE-A3/-A6 bind to the ubiquitin E3
ligase TRIM28, and a screen revealed AMPK-a1 to be a target
for polyubiquitylation by this complex, with consequent
proteasomal degradation. Consistent with this, knockdown
of MAGE-A3/A6 or TRIM28 in tumour cells increased
the expression of AMPK-a1 and triggered the expected
changes in metabolism and signalling, including inhibition ofmTORC1. Finally, various human tumour cells that express
MAGE-A3/-A6 have reduced levels of AMPK-a1 protein [171].
Another cancer-associated ubiquitin ligase, UBE2O, tar-
gets degradation of a2, the other catalytic subunit isoform
of AMPK [172]. Knockout of Ube2o attenuated tumour devel-
opment in mouse models of both breast and prostate cancer,
supporting the idea that the protein has tumour-promoting
functions. A search identified AMPK-a2 as an UBE2O-inter-
acting protein that is targeted for polyubiquitylation and
proteasomal degradation, and the levels of a2 but not a1
were upregulated in tissues from Ube2o2/2 mice. A human
colon carcinoma cell line also grew less rapidly in mouse
xenografts when UBE2O was knocked down using shRNA,
and this was reversed by concurrent knockdown of AMPK-a2
but not -a1. The UBE2O gene is located in humans at 17q25, a
region amplified in up to 20% of breast, bladder, liver and
lung carcinomas. Using immunohistochemistry of human
breast tumours, there was a negative correlation between
expression of UBE2O and AMPK-a2, but a positive correlation
between UBE2O expression and S6 phosphorylation, a marker
for the mTORC1 pathway [172].
5.2. AMPK—a tumour promoter?
Despite the evidence discussed in the previous section that
AMPK-a1 and -b1 are tumour suppressors that protect against
the development of B- and T-cell lymphomas as well as pros-
tate cancer, other studies suggest that AMPK may protect the
tumour cells (rather than the patient), and thus promote
tumour formation, at least when disease is already established.
Rathmell’s group used a different model of T-ALL in which
oncogenicNOTCH1was expressed in vitro inmurine haemato-
poietic stem cells that carried a floxed AMPK-a1 gene and
Cre recombinase driven by a tamoxifen-inducible promoter.
These were multiplied in irradiated mice, and then injected
into irradiated secondary recipient mice. After a period of
10 days to allow disease to become established, the mice
were then treated with tamoxifen to acutely delete AMPK-a1
in the T-ALL cells. In this model, knocking out AMPK-a1
reduced the recovery of T-ALL cells in spleen, lymph nodes
and bone marrow, and enhanced survival of the mice [173].
Thus, once T-ALL tumour cells have developed the presence
of AMPK-a1 appears to enhance T-ALL cell viability and
reduce mouse survival. While AMPK therefore acts as a
tumour suppressor during the development of T-ALL [167],
once the tumours have occurred it appears to paradoxically
switch to being a tumour promoter instead.
Another study using a mouse model of acute myeloid leu-
kaemia (AML) also concluded that AMPK acted as a tumour
promoter [174]. Here, mice carrying floxed alleles of Prkaa1
and Prkaa2, as well as Cre recombinase expressed from the
Mx1 promoter, were injected with poly(I:C) to delete AMPK-
a1 and -a2 from haematopoietic cells, with mice lacking
Mx1-Cre as controls. Haematopoietic progenitor cells from
these mice were then transduced with retroviruses expressing
three different cancer-promoting gene fusions (MLL-AFP,
MOZ-TIF2 or BCR-ABL) and were then transplanted into
irradiated recipient mice. The absence of AMPK from the
leukaemia-initiating cells either delayed the onset of disease
(BCR-ABL) or enhanced mouse survival (MLL-AFP or MOZ-
TIF1). Thus, the presence of AMPK was required to maintain
full leukaemogenic potential of the cells in these models. Evi-
dence was provided that this was because the lack of AMPK
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13increased the recovery of reactive oxygen species (ROS) in leu-
kaemia-initiating cells from bone marrow, correlating with
decreased ratios of reduced : oxidized NADP and glutathione,
and increased DNA damage. This was ascribed to a reduced
glucose uptake via GLUT1, which is regulated by AMPK via
phosphorylation of TXNIP (see §4.1). The authors also pro-
posed that the leukaemia-initiating cells lacking AMPK were
particularly vulnerable to stress in the bone marrow, because
the glucose concentrations were lower than in peripheral
blood, especially under conditions of dietary restriction of the
mice [174].
Consistent with these findings, reduced survival of AMPK-
deficient human tumour cells undergoing stress has been
observed in several in vitro studies. For example, LKB1-null
tumour cells, or LKB1-expressing tumour cells with AMPK-
a1 knocked down using shRNA, were more susceptible to
cell death induced by glucose starvation or extracellular
matrix detachment, suggesting that AMPK activation pro-
tected against these insults [175]. In another example, a
synthetic lethal siRNA screen was carried out to detect protein
kinases required for survival of U2OS cells that over-expressed
the Myc oncogene from a tamoxifen-inducible promoter. One
of the top hits was AMPK-a1, which was also shown to be
activated during Myc over-expression [176].
Evidence that AMPK can promote tumours was also
obtained recently using a mouse model of lung cancer in
which the tumours develop in situ at their site of origin, and
in which the authors had ‘bitten the bullet’ by knocking out
both AMPK-a1 and -a2. Here, mice expressing Lox-STOP-
Lox alleles of the KRASG12D oncogene and firefly luciferase
were crossed with mice expressing floxed alleles of Tp53
(encoding p53) and/or Stk11 and/or Prkaa1 plus Prkaa2. To
model non-small cell lung carcinoma, Cre-recombinase was
delivered to the lungs by nasal inhalation of lentiviral vectors.
This procedure triggers recombination at twin loxP sites in a
small subset of lung epithelial cells, in which expression of
KRASG12D and luciferase would be switched on, and p53
and/or LKB1 and/or AMPK-a1/-a2 would be knocked out;
expression of luciferase also allowed tumours to be imaged
by bioluminescence, and thus their growth to be monitored
in vivo. Knockout of LKB1 enhanced growth in tumours expres-
sing mutant K-Ras as reported previously [177] but, by
contrast, knockout of both AMPK-a1 and -a2 was found to
cause reductions in the size and number of lung tumours,
especially in tumours expressing mutant K-Ras and lacking
p53. Overall, these results confirmed that LKB1 is a tumour
suppressor in non-small cell lung cancer as expected, while
the presence of either AMPK-a1 or -a2 promoted tumour
growth [178].6. Evidence from analysis of human cancer
genomes
Although most of the evidence discussed in §5 was obtained
in mouse models of cancer, comparison of genetic alterations
in genes encoding the LKB1-AMPK pathway in biopsies of
human cancers, compared with normal tissue, can also pro-
vide useful clues about roles of the pathway in human
cancer. The cBioPortal database (http://www.cbioportal.
org/ [179,180]) provides a particularly user-friendly way to
analyse the many studies of human cancer of this type that
have been performed to date. Figure 6 summarizes geneticchanges in the STK11 gene encoding LKB1, and all seven
genes encoding subunit isoforms of AMPK, extracted from
cBioPortal in April 2019. Each vertical bar represents an indi-
vidual cancer genome project, with the height of the bar
representing the percentage of cases where genetic alterations
were seen (only studies with changes in greater than or equal
to 3% of cases are shown). Since LKB1 is a known tumour
suppressor, one would expect to observe mainly mutations
(green bars) or deletions (blue bars) when analysing STK11.
This is indeed generally the case (figure 6a), although there
are some anomalous cancer studies where gene amplification
was observed instead (red bars), particularly in pancreatic
and prostate cancers. By contrast, changes in the PRKAA1
gene, encoding AMPK-a1, were mostly amplifications (note
preponderance of red bars in figure 6b), which is more con-
sistent with the idea that AMPK-a1 can act as a tumour
promoter. An important caveat is that gene amplifications
in cancer usually involve whole segments of chromosomes
rather than individual genes. It was therefore possible that
the PRKAA1 gene is located close to an oncogene for which
amplification was being selected, with PRKAA1 simply
accompanying it as an innocent bystander. However, an
argument against that possibility comes from analysis of
concurrent genetic changes in STK11 and PRKAA1 in single
cancer studies, such as the 230 cases of lung adenocarcinoma
in The Cancer Genome Atlas (figure 7) [181]. In that
study, the STK11 gene was either deleted or mutated (mostly
truncations or missense mutations predicted to cause loss of
function) in 43 cases (19%) and PRKAA1 was amplified in 22
(10%). However, these changes never coincided (p ¼ 0.005),
which would be expected to occur by random chance if they
were occurring independently. The most frequent mutations
in this study of lung adenocarcinoma were in the KRAS
(36%) and TP53 genes (47%), encodingK-Ras and p53. Interest-
ingly, amplification of PRKAA1was almost mutually exclusive
with mutations in KRAS ( p ¼ 0.005), but co-occurred with
mutations in TP53 ( p, 0.001).
Why should amplification of the AMPK-a1 gene be
mutually exclusive with mutations in the LKB1 gene? The
answer to this seems obvious, because there would be little
point in over-expressing AMPK-a1 if LKB1 was not present
to phosphorylate and activate it. These considerations suggest
that PRKAA1 amplification is being selected for, rather than
just being an innocent bystander. However, why amplification
of the AMPK-a1 gene should co-occur withmutations in p53 is
less obvious. The classical role of p53 [182] is to become stabil-
ized or activated in response to DNA damage, and to cause a
G1 cell cycle arrest in order to allow time for the damage to
be repaired, which it achieves by inducing transcription of
genes such as the G1 cyclin-dependent kinase inhibitor
p21CIP1 (CDKN1A). Intriguingly, as already discussed in
§2.5, AMPK complexes containinga1 are also activated by gen-
otoxic agents such as etoposide, and can trigger a similar G1
cell cycle arrest [11]. It therefore seems possible that PRKAA1
amplification may be selected for in p53-null tumours because
over-expression of AMPK-a1 can compensate to some extent
for p53 loss, and could thus enhance survival of p53-null
tumour cells undergoing genotoxic stress.
In marked contrast to the frequent amplification of the
PRKAA1 gene in cancer, the PRKAA2 gene encoding AMPK-
a2 is much more often mutated (note preponderance of green
bars in figure 6c). Interestingly, all six of the cancer studies
where the gene was most frequently mutated (10–23% of
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14cases)were of skin cancer ormelanoma. The reasons for this are
not clear, but separate analysis showed that in all of the skin
cancer/melanoma studies listed in cBioPortal there were80 mutations affecting AMPK-a2 and just 10 affecting a1.
Although it is not yet clear how many of the former cause
loss of function in a2 complexes, these results suggest that
truncating mutation (putative driver)
PRKAA1: 10%
STK11: 19%
KRAS: 36%
TP53: 47%
inframe mutation (putative driver) missense mutation (unknown significance)missense mutation (putative driver)
amplification no changesdeep deletion
Figure 7. Co-occurrence or mutual exclusion of genetic alterations in the PRKAA1 (AMPK-a1), STK11 (LKB1), KRAS (K-Ras) and TP53 ( p53) genes in human lung
adenocarcinoma. Results were generated using cBioPortal from the results of a single study [181]. Each column of vertically aligned bars represents a single case;
cases with no alterations in any of the genes are not shown.
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15AMPK-a2 may play a tumour suppressor role in skin cancer
and melanoma.
When it comes to the AMPK-b subunits, there was a strik-
ing difference between the behaviour in human cancers of the
PRKAB1 and PRKAB2 genes, encoding b1 and b2 (figure 6d,e).
While genetic changes in PRKAB1were detected in just a very
small number of cancer studies andwere quite variable in gen-
etic type, the PRKAB2 gene was frequently amplified in
numerous different cancers (note preponderance of red bars
in figure 6e), suggesting, if anything, a tumour promoter role.
Since the C-terminal domain of the b subunit (b-CTD) forms
the ‘core’ of the heterotrimeric AMPK complex (see §2.2),
over-expression of b2 may perhaps help to stabilize and
increase expression of the a and g subunits, even when the
genes encoding those subunits lack genetic alterations. How-
ever, why it should only be the gene encoding b2, and not
b1, that is amplified remains unclear.
Alterations in the genes encoding the three g subunits tend
to occur at a lower frequency than those encoding the a and b
subunits, and are more mixed in genetic type (figure 6f–h).
However, there were some interesting findings, such as the
41% of cases (albeit only five out of 12) in which the PRKAG1
gene was deleted in adenoid cystic breast cancer [183].
Looking at the genetic alterations occurring in the genes
encoding LKB1 and AMPK subunits in human cancer, one
striking observation is that all eight genes are frequently ampli-
fied in neuroendocrine prostate cancer (labelled NE prostate in
figure 6). This is a subset of prostate cancer that has become
resistant to anti-androgen treatment [184]. The significance of
this intriguing observation remains unclear at present.7. Conclusion—is AMPK a tumour
suppressor or a tumour promoter,
or both?
In this final section we will attempt to reconcile the apparently
conflicting reports that AMPK can variously act to promote or
suppress tumorigenesis. Our view is that AMPK can act either
as a tumour suppressor or a tumour promoter, depending on
the context. It can be argued that in all of the mouse studies
where a tumour suppressor role was supported (e.g. in the
Em-Myc model of B-cell lymphoma [163], the p53-null [166]
and PTEN-null [167] models of T-cell lymphoma and the
PTEN-null model of prostate cancer [170]), AMPK function
had been knocked out prior to tumorigenesis. For example,
in the Em-Myc model [185], loss of AMPK-a1 would
have occurred during embryogenesis whereas, althoughover-expression of Myc in pre-B cells has certainly occurred
by 35–50 days of age [186], lymphomas do not start to arise
until 50 days and their median onset is 80 days [187]. Thus,
events additional to Myc over-expression must occur before
lymphomas are generated. The same applies to the PTEN
knockout model of T-ALL, where the Lck promoter-driven
knockout of PTEN and/or AMPK-a1 would have occurred
by 30 days of age but lymphomas did not start to arise until
later (figure 5).
On the other hand, in those mouse models of cancer
where AMPK appeared to be acting as a tumour promoter,
it can be argued that the knockout of AMPK usually occurred
either simultaneous with, or even after, tumorigenesis had
been initiated. For example, in the study of T-ALL by Kishton
et al. [173] (§5.2), transformation was generated in vitro by
forced expression of an oncogenic mutant of Notch1, and
the T-ALL cells were then transferred to irradiated recipient
mice and disease allowed to become established prior to
AMPK being knocked out by treatment with tamoxifen. It
is particularly instructive to compare this model with our
own more recently published model of T-ALL [167], where
AMPK-a1 had been specifically knocked out in T-cell pro-
genitors prior to lymphomas starting to occur, in which
basal AMPK was clearly protecting against development
of lymphomas, and in which activation of AMPK using
phenformin provided further protection.
Coming to other mouse studies that support a tumour
promoter role for AMPK, in the autochthonous model of
non-small cell lung cancer [178], knockout of AMPK would
have occurred simultaneously with expression of mutant
K-Ras and loss of p53, which may have been sufficient to trig-
ger tumorigenesis on their own. The only study that
supported a tumour promoter role but where AMPK had
been knocked out prior to disease onset was the model of
AML by Saito et al. [174]. However in that case (as in the
study of T-ALL by Kishton et al. [173]) transformation had
been achieved by enforced expression of oncogenes in vitro
in haematopoietic progenitor cells, and the real test of the
role of AMPK was in the survival and/or proliferation of
the leukaemia cells in vivo in irradiated recipient mice.
It can be argued that these two studies, by carrying out
transformation in vitro, may have been less likely to detect
a tumour suppressor role of AMPK.
Overall we propose that, when loss of AMPK occurs prior
to initiation of tumorigenesis in vivo, this would remove the
restraints on the mTORC1 pathway and unleash other biosyn-
thesis processes and the cell cycle, thus transforming the cells
into a metabolic and proliferative state that is primed for
tumour formation. Under these circumstances, AMPK acts as
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16a tumour suppressor, and AMPK activators may provide
additional protection against tumorigenesis, such as the
effect of phenformin in T-ALL [167]. These results suggest
that AMPK activators might one day find a place in providing
protection against cancer, perhaps in individuals who are at
high risk of developing the disease. If biguanides are used, it
might also make sense to use phenformin which, being more
membrane permeable than metformin even in the absence of
a transporter, is much more likely to activate AMPK in the
tumour progenitor cells. Although phenformin was with-
drawn for treatment of type 2 diabetes because of the risk of
life-threatening lactic acidosis, the risk of this complication
was actually quite low (64 cases per 100 000 patient-years
[188]), and might be more acceptable in the context of cancer
rather than diabetes. Alternatively, some of the other AMPK
activators discussed in §3 might perhaps be developed for
this purpose.
We also propose that, once the cancer cells have started to
grow in vivo, AMPK switches from being a tumour suppressor
to a tumour promoter (like the transformation of the benevo-
lent Dr Jekyll into the malevolent Dr Hyde in Stevenson’s
novel!). Under these circumstances, the role of AMPK is to pro-
tect the cell inwhich it is expressed, irrespective ofwhether that
cell is a cancer cell or a normal cell. By protecting cancer cellsagainst stresses such as shortage of oxygen or nutrients, or oxi-
dative or genotoxic stress, AMPKwould enhance their survival
and thus, in the long term, promote growth of tumours. Under
these circumstances, AMPK is acting as a tumour promoter,
which suggests that AMPK inhibitors might be efficacious in
treatment of cancer. They may be particularly effective: (i) in
caseswhere thePRKAA1 orPRKAB2 genes are amplified, caus-
ing AMPK over-expression; (ii) when given in combination
with genotoxic treatments such as etoposide or radiotherapy,
thus reducing the viability of tumour cells during such thera-
pies. At present we do not have any well-characterized and
specific inhibitors of AMPK (see §3.4), but future work can
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